NCT04011033View on ClinicalTrials.gov

Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

March 1, 2020

Study Completion Date

October 1, 2023

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

iNKT cells

5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.

DRUG

Human recombinated Interleukin-2

IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.

PROCEDURE

TAE/TACE

TAE/TACE will be conducted to all patients at 0th week and 4th week.

Trial Locations (1)

100069

Beijing Youan Hospital,Capital Medical University, Beijing

All Listed Sponsors
collaborator

Beijing Shijitan Hospital, Capital Medical University

OTHER

collaborator

Beijing Ditan Hospital

OTHER

lead

Beijing YouAn Hospital

OTHER

NCT04011033 - Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | Biotech Hunter | Biotech Hunter